Truist analyst David MacDonald lowered the firm’s price target on UnitedHealth (UNH) to $610 from $625 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as “mixed”, with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $600 from $605 at Piper Sandler
- Dow Jones 2024 Wrap-Up: December Drops Don’t Stop Annual Gains
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025
- UnitedHealth doctors helped it collect billions from Medicare, WSJ says
- Netflix draws big viewership for NFL Christmas games: Morning Buzz